365 days into role - alongside passionate & committed colleagues, driven by an amazing purpose and mission! #Sandoz
Pierre Bourdage via LinkedIn
Sep 21, 2020
365 exciting, inspiring and sometimes challenging days have passed since I started my role as Head of Biopharmaceuticals at Sandoz. While previously serving in Strategy & Portfolio, I still couldn’t be exactly sure what to expect (which I’m sure has been the experience for everyone in 2020 so far), but I was clear on the exciting opportunity ahead to lead a business unit that has the ability to improve biologic access and affordability for millions of patients. I feel very lucky to contribute to this amazing purpose and mission.
Among many other things, the global response to the COVID-19 pandemic has reinforced how important access to high-quality, affordable medicines are for patients, healthcare systems, and society as a whole. In the face of this unprecedented challenge, I am very proud of the way both Sandoz and Novartis have responded to this pandemic, doing whatever possible to deliver stable supply and access to our biologics and medicines during a time when they are needed most, and guarantee stable pricing on core generics medicines currently in scope of COVID-19 treatment pathways.
In general, it is the commitment, passion and energy of all the colleagues I’ve worked alongside over the past year, even in “normal times”, that I continue to find inspiring. I’m very proud that as a team we’ve continued to expand our portfolio of biosimilars while working tirelessly to address the barriers to uptake. There is a real sense of purpose at Sandoz, with everyone focused on doing everything they can to improve access to biologics and other medicines for people who really need them.
It has been a fascinating journey so far; one that has challenged and taught me something new every day and helped me push boundaries alongside my colleagues. And while a return to normality is still uncertain, I am truly excited at the opportunity to build on the great work from this previous year and continue to drive positive change for healthcare systems and the patients we serve.